Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCSGJ2)

• Drug Name: BAY1163877 Drug Info
• Synonyms: Rogaratinib

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 71611869
  CAS Number: CAS 1443530-05-9
  TTD Drug ID: DMCSGJ2

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor receptor (FGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erdafitinib	DMI782S	Bladder cancer	2C94	Approved	[4]
Futibatinib	DMWM4D0	Intrahepatic cholangiocarcinoma	2C12.10	Approved	[5]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[6]
HIF-1alpha	DM4OQRD	Lymphoma	2A80-2A86	Phase 4	[7]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[6]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[6]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
ICP-192	DM524GR	Bladder cancer	2C94	Phase 2	[9]
PRN1371	DMR7BAO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
PD173074	DMP0N4U	Nasopharyngeal carcinoma	2B6B	Investigative	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor (FGFR)	TT0LF7H	NOUNIPROTAC	Antagonist	[3]

References

• [1] ClinicalTrials.gov (NCT04040725) Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT01976741) Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor. U.S. National Institutes of Health.
• [3] Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
• [8] The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
• [9] Clinical pipeline report, company report or official report of InnoCare Pharma.